The goal of this study is to determine the prevalence of germline mutations in men with prostate cancer to assess the efficacy of current germline testing guidelines and implications for follow up and family testing.
Why should you participate?
- Expand knowledge of genetic testing and its application within their practices
- Genetic testing may provide additional clinical information to patients that might impact their treatment, follow up and management of unaffected family members
- Participate in possible publications that may impact change in testing guidelines
- Meet National Cancer Center research study enrollment requirements
Click to hear Dr Neal Shore, Principal Investigator on the Invitae Prostate Cancer Study discuss the importance of this study and how germline genetic testing in prostate cancer may help patients and their families.
Neal D. Shore, MD, is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 250 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Society of Urologic Oncology Clinical Trials Consortium, and the Large Urology Group Practice Association. He also is a member of the AUA Data Committee, the Bladder Cancer Advocacy Think Tank and the editorial board of Urology Times and is the Immediate Past President of LUGPA.
 |
Study authors recommend all prostate cancer patients receive genetic testingThe largest study to date on the genetics of prostate cancer has found that 17% of prostate cancer patients have a disease-causing genetic variant associated with more aggressive disease and poorer health outcomes. Previously, that number was thought to be closer to 12%.What's more, the factors frequently used to identify patients who qualify for testing, including family history and Gleason scores, did not correlate with positive variants in the 3,600 patients tested.LEARN MORE |
|---|
The goal of this study is to determine the prevalence of germline mutations in men with prostate cancer to assess the efficacy of current germline testing guidelines and implications for follow up and family testing.
Why should you participate?
- Expand knowledge of genetic testing and its application within their practices
- Genetic testing may provide additional clinical information to patients that might impact their treatment, follow up and management of unaffected family members
- Participate in possible publications that may impact change in testing guidelines
- Meet National Cancer Center research study enrollment requirements
LEARN MORE
